NUVL
NUVL
NASDAQ · Biotechnology

Nuvalent Inc-A

$98.00
+1.85 (+1.92%)
As of Mar 25, 9:48 PM ET ·
Financial Highlights (FY 2025)
Revenue
1.56B
Net Income
-302,764,100
Gross Margin
53.1%
Profit Margin
-19.4%
Rev Growth
+10.6%
D/E Ratio
0.68
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 53.1% 53.1% 53.1%
Operating Margin -26.2% -23.3% -27.3%
Profit Margin -19.4% -26.0% -21.8%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 1.56B 1.45B 1.21B
Gross Profit 830.85M 772.13M 643.79M
Operating Income -410,568,297 -338,772,092 -330,957,361
Net Income -302,764,100 -377,638,036 -264,320,064
Gross Margin 53.1% 53.1% 53.1%
Operating Margin -26.2% -23.3% -27.3%
Profit Margin -19.4% -26.0% -21.8%
Rev Growth +10.6% +5.5% +20.0%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 3.27B 3.00B 2.91B
Total Equity 4.78B 4.59B 5.01B
D/E Ratio 0.68 0.65 0.58
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -533,448,597 -500,050,490 -459,692,337
Free Cash Flow -391,442,676 -279,670,611 -274,115,194